Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit

OncoImmunology

Volumn 6, Issue 2, 2017, Pages

  Tarhini, Ahmad A ^a,b   Lin, Yan ^b   Lin, Hui Min ^b   Vallabhaneni, Priyanka ^b   Sander, Cindy ^b   LaFramboise, William ^a,b   Hamieh, Lana ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytotoxic T lymphocyte antigen 4; gene expression profiling; ipilimumab; melanoma; neoadjuvant

Indexed keywords

ALPHA INTERFERON; IPILIMUMAB;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL OUTCOME; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MRNA EXPRESSION ASSAY; NEOADJUVANT THERAPY; PROGRESSION FREE SURVIVAL; PROTEIN MICROARRAY; QUALITY CONTROL; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PURIFICATION; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; VERY ELDERLY;

EID: 85011826998     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1231291     Document Type: Article

References (20)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
2. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
3. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
5. Tarhini AA, Kirkwood JM. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? J Clin Oncol 2012; 30:3773-6; PMID:23008298; http://dx.doi.org/10.1200/JCO.2012.44.9975
6. Schadendorf DHF, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. European Cancer Congress 2013 (ECCO-ESMO-ESTRO), 2013
7. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma:the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17; PMID:8558223
8. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab vs. placebo after complete resection of high-risk stage III melanoma (EORTC 18071):a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522-30; PMID:25840693; http://dx.doi.org/10.1016/S1470-2045(15)70122-1
9. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PloS One 2014; 9:e87705; PMID:24498358; http://dx.doi.org/10.1371/journal.pone.0087705
10. Tarhini AA. Immunotherapy of melanoma. Curr Mol Pharmacol 2015; PMID:26177647
11. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996; 4:535-43; PMID:8673700; http://dx.doi.org/10.1016/S1074-7613(00)80480-X
12. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18:206-13; PMID:16464564; http://dx.doi.org/10.1016/j.coi.2006.01.011
13. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 2009; 14:848-61; PMID:19648604; http://dx.doi.org/10.1634/theoncologist.2009-0028
14. Clinical Trials.gov [Internet]. Bethesda (MD):national Library of Medicine (US). 2000 Feb 29 - Identifier:NCT01274338, Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery. 2011 January 8 [cited 2016 March 24]; [about 7 screens] p https://clinicaltrials.gov/ct2/show/NCT01274338
15. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69:3077-85; PMID:19293190; http://dx.doi.org/10.1158/0008-5472.CAN-08-2281
16. Louahed J, Gruselle O, Gaulis S, Coche T, Eggermont AM, Kruit W, Dreno B, Chiarion SV, Lehmann F, Brichard VG. Expression of defined genes identified by pre-treatment tumor profiling:association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. J Clin Oncol. 2008; 26(suppl):9045.
17. Vansteenkiste JF, Zielinski M, Dahabreh IJ, Linder A, Lehmann F, Gruselle O, Therasse P, Louahed J, Brichard VG. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(suppl):7501
18. Sullivan RJ, Hoshida Y, Brunet J, Tahan S, Aldridge J, Kwabi C, Gardiner E, McDermot D, Golub T, Atkins MA. A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol 2009; 27:15S:9003
19. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011; 61:1019-31; PMID:22146893; http://dx.doi.org/140.1007/s00262-011-1172-6
20. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9:204; PMID:22123319; http://dx.doi.org/10.1186/1479-5876-9-204